GX-H9: Interim Phase II data

Interim data from 13 adults with growth hormone deficiency in an open-label Phase II trial showed that once-weekly 0.1 mg/kg subcutaneous GX-H9 for 12 weeks increased mean insulin-like growth factor-1...